104 related articles for article (PubMed ID: 28446474)
1. Letter by Westerink and Visseren Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial".
Westerink J; Visseren F
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):e53. PubMed ID: 28446474
[No Abstract] [Full Text] [Related]
2. Response by Takase and Matoba to Letter Regarding Article, "Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial".
Takase S; Matoba T
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):e54. PubMed ID: 28446475
[No Abstract] [Full Text] [Related]
3. Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial.
Takase S; Matoba T; Nakashiro S; Mukai Y; Inoue S; Oi K; Higo T; Katsuki S; Takemoto M; Suematsu N; Eshima K; Miyata K; Yamamoto M; Usui M; Sadamatsu K; Satoh S; Kadokami T; Hironaga K; Ichi I; Todaka K; Kishimoto J; Egashira K; Sunagawa K
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):350-358. PubMed ID: 27932353
[TBL] [Abstract][Full Text] [Related]
4. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Ono T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
J Cardiol; 2015 Oct; 66(4):353-8. PubMed ID: 25577723
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
Tsujita K; Yamanaga K; Komura N; Sakamoto K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
Eur J Prev Cardiol; 2016 Sep; 23(14):1524-8. PubMed ID: 27296705
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
Hiro T; Hirayama A; Ueda Y; Komatsu S; Matsuoka H; Takayama T; Ishihara M; Hayashi T; Saito S; Kodama K;
J Cardiol; 2014 Dec; 64(6):501-7. PubMed ID: 24725763
[TBL] [Abstract][Full Text] [Related]
7. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
8. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
9. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe: cholesterol lowering and beyond.
Bays HE; Neff D; Tomassini JE; Tershakovec AM
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):447-70. PubMed ID: 18402536
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol.
Mori Y; Hirano T
Metabolism; 2012 Mar; 61(3):379-88. PubMed ID: 21868047
[TBL] [Abstract][Full Text] [Related]
12. Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial.
Fujisue K; Nagamatsu S; Shimomura H; Yamashita T; Nakao K; Nakamura S; Ishihara M; Matsui K; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Sakamoto K; Izumiya Y; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
Int J Cardiol; 2018 Oct; 268():23-26. PubMed ID: 29925472
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe: a novel option for lowering cholesterol.
Davidson MH
Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
[TBL] [Abstract][Full Text] [Related]
14. Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Koh KK
Circulation; 2018 Jun; 137(24):2660-2661. PubMed ID: 29891624
[No Abstract] [Full Text] [Related]
15. Pharaceutical chemical characterization of ezetimibe.
Blanka SS; Gabor O; Hajnal K
Acta Pharm Hung; 2016; 86(4):133-139. PubMed ID: 29870599
[TBL] [Abstract][Full Text] [Related]
16. Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Thomopoulos C; Michalopoulou H
Circulation; 2018 Jun; 137(24):2656-2657. PubMed ID: 29891622
[No Abstract] [Full Text] [Related]
17. Add-on ezetimibe reduces small dense low-density lipoprotein cholesterol levels without affecting absorption of eicosapentaenoic acid in patients with coronary artery disease: a pilot study.
Kubo M; Miyoshi T; Kimura T; Noda Y; Kohno K; Nakamura K; Morita H; Ito H
Am J Cardiovasc Drugs; 2014 Oct; 14(5):387-92. PubMed ID: 24915983
[TBL] [Abstract][Full Text] [Related]
18. Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Cordero A; Bertomeu-González V; Rodriguez-Mañero M
Circulation; 2018 Jun; 137(24):2658-2659. PubMed ID: 29891623
[No Abstract] [Full Text] [Related]
19. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
20. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
